Inomoto T, Shirakami A, Kawauchi S, Shigekiyo T, Saito S, Miyoshi K, Morita T, Iwanaga S
Blood. 1987 Feb;69(2):565-9.
A mutant prothrombin, designated prothrombin Tokushima, was purified from plasma of a proband with 12% of normal plasma clotting activity and 42% of normal prothrombin antigen. The purified preparation gave a single band with the same mobility as that of "prothrombin" by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The factor Xa-catalyzed proteolysis of prothrombin Tokushima examined by SDS-PAGE was found to be identical to that of "prothrombin." Subsequently thrombin Tokushima was prepared by CM-Sepharose CL-6B column chromatography after prothrombin activation by factor Xa. The molecular weight of thrombin Tokushima estimated by SDS-PAGE was identical to that of "thrombin." Thrombin Tokushima exhibited less than 22% of normal clotting activity, and the value of kcat/Km (mumol/L-1 second-1) was less than one tenth of that of "thrombin" when Boc-Val-Pro-Arg-4-methylcoumaryl-7-amide was used as a substrate. However, active site titration using p-nitrophenyl-p'-guanidinobenzoate failed to detect any difference between the two. Thrombin Tokushima was 2.5% as effective as "thrombin" in inducing platelet aggregation. Interaction of thrombin Tokushima with antithrombin III was much slower than "thrombin" when followed by SDS-PAGE. Based on the residual thrombin activity, it was 33% as effective as "thrombin" in forming a complex with antithrombin III. These results indicate that the molecular defect resides in the thrombin portion of prothrombin Tokushima and that the binding sites for various substrates appear to be greatly impaired.
从一名先证者的血浆中纯化出一种突变凝血酶原,命名为凝血酶原德岛,其血浆凝血活性为正常的12%,凝血酶原抗原为正常的42%。通过十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS-PAGE),纯化后的制剂呈现出一条与“凝血酶原”迁移率相同的单一谱带。通过SDS-PAGE检测发现,凝血酶原德岛经因子Xa催化的蛋白水解过程与“凝血酶原”相同。随后,在因子Xa激活凝血酶原后,通过CM-琼脂糖CL-6B柱色谱法制备了德岛凝血酶。通过SDS-PAGE估算,德岛凝血酶的分子量与“凝血酶”相同。德岛凝血酶的凝血活性低于正常水平的22%,当以Boc-Val-Pro-Arg-4-甲基香豆素-7-酰胺为底物时,其kcat/Km(μmol/L-1秒-1)值不到“凝血酶”的十分之一。然而,使用对硝基苯基-p'-胍基苯甲酸酯进行活性位点滴定未能检测到两者之间的任何差异。在诱导血小板聚集方面,德岛凝血酶的效力仅为“凝血酶”的2.5%。通过SDS-PAGE跟踪发现,德岛凝血酶与抗凝血酶III的相互作用比“凝血酶”慢得多。基于残留的凝血酶活性,在与抗凝血酶III形成复合物方面,它的效力为“凝血酶”的33%。这些结果表明,分子缺陷存在于凝血酶原德岛的凝血酶部分,并且各种底物的结合位点似乎受到了极大的损害。